Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Biosimilar Hearing Will Consider Whether 'Umbrella' Exclusivity Policy Warranted

Jul 25 2018

• By Derrick Gingery

mangled umbrella — • Source: brlnpics123

Related Content

Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum

Jun 22 2018

Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition

Jul 23 2018

Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars

Jul 19 2018

Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products

Jul 17 2018

Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?

May 10 2018

FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models

Jul 19 2018

Biologics Exclusivity: GPhA Making Last Stand In Pacific

Jan 05 2015

NORD Slams Orphan Indication Discussion At Biosimilar Advisory Committee

Feb 15 2016

Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim

Apr 06 2016

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sep 17 2015

Related Companies

Celltrion, Inc.

Johnson & Johnson

Additional Topics

United States Biosimilars Regulation FDA Biologics BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window